The University of the West of England, Bristol, UK.
Int J Dermatol. 2022 Nov;61(11):1303-1310. doi: 10.1111/ijd.15937. Epub 2021 Oct 15.
Primary palmar hyperhidrosis (PH) can have a significantly negative impact on an individual's quality of life. Currently, there appears to be no review of the effectiveness of the different interventions for its management.
A systematic review was performed using PRISMA guidelines, the Cochrane Database, and MEDLINE (OVID) to identify relevant studies published from 1997 to 2017.
Of the 574 references yielded, six met the inclusion criteria and were analyzed for this review. Two studies evaluated the use of oral oxybutynin as an anticholinergic treatment for PH; this demonstrated high efficacy with over 80% of patients reporting symptom improvement; dry mouth was the most common adverse effect reported. One study looking at the use of iontophoresis reported 81% improvement in patients' symptoms. One randomized, double-blind, trial looked at the use of botulinum toxin A injections for the treatment of PH; it reported 90% of patients experienced an improvement in PH. The remaining two studies evaluated the use of endoscopic thoracic sympathectomy (ETS) in PH, and both reported over 95% patient symptom improvement.
There are few good quality studies evaluating the treatment of primary PH. Based on the little available evidence, the interventions reviewed significantly improve the symptoms of PH. Anticholinergic medications are considered effective and safe. Both iontophoresis and botulinum toxin provided patients with symptom relief when administered regularly. ETS was reported as successful in the reduction of PH, however, it carries significant adverse effects such as compensatory sweating and the potential of complications associated with surgery.
原发性手掌多汗症(PH)会对个体的生活质量产生重大负面影响。目前,似乎没有对其管理的不同干预措施的有效性进行综述。
使用 PRISMA 指南、Cochrane 数据库和 MEDLINE(OVID)系统地进行了综述,以确定从 1997 年至 2017 年发表的相关研究。
在 574 篇参考文献中,有 6 篇符合纳入标准,并对其进行了分析。两项研究评估了口服奥昔布宁作为 PH 的抗胆碱能治疗;这表明其疗效很高,超过 80%的患者报告症状改善;最常见的不良反应是口干。一项研究观察了离子电渗疗法在 PH 中的应用,报告称 81%的患者症状得到改善。一项随机、双盲试验研究了肉毒杆菌毒素 A 注射治疗 PH 的效果;报告称 90%的患者 PH 得到改善。其余两项研究评估了胸腔镜胸交感神经切除术(ETS)在 PH 中的应用,均报告称超过 95%的患者症状改善。
评估原发性 PH 治疗的高质量研究很少。根据有限的可用证据,所审查的干预措施显著改善了 PH 的症状。抗胆碱能药物被认为是有效和安全的。离子电渗疗法和肉毒杆菌毒素 A 注射都能定期缓解患者的症状。ETS 被报道为降低 PH 的成功方法,但它会带来显著的不良反应,如代偿性出汗以及与手术相关的潜在并发症。